Literature DB >> 14624324

Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry.

Graham Lappin1, R Colin Garner.   

Abstract

Accelerator mass spectrometry (AMS) is an extremely sensitive nuclear physics technique developed in the mid-70's for radiocarbon dating of historical artefacts. The technique centres round the use of a tandem Van de Graaff accelerator to generate the potential energy to permit separation of elemental isotopes at the single atom level. AMS was first used in the early 90's for the analysis of biological samples containing enriched 14C for toxicology and cancer research. Since that time biomedical AMS has been used in the study of (1) metabolism of xenobiotics in animals and humans (2) pathways of drug metabolism (3) biomarkers (4) metabolism of endogenous molecules including vitamins (5) DNA and protein binding studies and (6) clinical diagnosis. A new drug development concept which relies on the ultrasensitivity of AMS known as human microdosing (Phase 0) is being used to obtain early human metabolism information of candidate drugs arising out of discovery. These various aspects of AMS are reviewed in this article and a perspective on future applications of AMS provided.

Entities:  

Year:  2003        PMID: 14624324     DOI: 10.1007/s00216-003-2348-5

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  14 in total

Review 1.  Accelerator mass spectrometry-enabled studies: current status and future prospects.

Authors:  Ali Arjomand
Journal:  Bioanalysis       Date:  2010-03       Impact factor: 2.681

2.  Towards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry.

Authors:  Sang Soo Hah; Paul T Henderson; Kenneth W Turteltaub
Journal:  Bioorg Med Chem Lett       Date:  2010-03-07       Impact factor: 2.823

Review 3.  Mass balance studies, with a focus on anticancer drugs.

Authors:  Jan H Beumer; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  The phase 0 microdosing concept.

Authors:  R Colin Garner; Graham Lappin
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

5.  Measurement of 7,8-dihydro-8-oxo-2'-deoxyguanosine metabolism in MCF-7 cells at low concentrations using accelerator mass spectrometry.

Authors:  Sang Soo Hah; Janna M Mundt; Hyung M Kim; Rhoda A Sumbad; Kenneth W Turteltaub; Paul T Henderson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-25       Impact factor: 11.205

Review 6.  Quantifying exploratory low dose compounds in humans with AMS.

Authors:  Stephen R Dueker; Le T Vuong; Peter N Lohstroh; Jason A Giacomo; John S Vogel
Journal:  Adv Drug Deliv Rev       Date:  2010-10-31       Impact factor: 15.470

7.  Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man.

Authors:  Ethan Hoffmann; Jeff Wald; Siva Lavu; John Roberts; Claire Beaumont; Jon Haddad; Peter Elliott; Christoph Westphal; Eric Jacobson
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

8.  Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats.

Authors:  Michael A Malfatti; Victoria Lao; Courtney L Ramos; Voon S Ong; Kenneth W Turteltaub
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

9.  Determining the pharmacokinetics and long-term biodistribution of SiO2 nanoparticles in vivo using accelerator mass spectrometry.

Authors:  Michael A Malfatti; Heather A Palko; Edward A Kuhn; Kenneth W Turteltaub
Journal:  Nano Lett       Date:  2012-10-17       Impact factor: 11.189

10.  A microdose study of ¹⁴C-AR-709 in healthy men: pharmacokinetics, absolute bioavailability and concentrations in key compartments of the lung.

Authors:  G Lappin; M J Boyce; T Matzow; S Lociuro; M Seymour; S J Warrington
Journal:  Eur J Clin Pharmacol       Date:  2013-06-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.